# MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia

> **NCT00501371** · PHASE3 · TERMINATED · sponsor: **Health Ever Bio-Tech Co., Ltd.** · enrollment: 85 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** MCS
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00501371
- **Lead sponsor:** Health Ever Bio-Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Study terminated for re-design. A new IND study (US FDA, July 2009) will be conducted in US and Taiwan. Termination not related to safety concerns.
- **Last updated:** 2011-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00501371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00501371, "MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00501371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*